Hereditary Hematological Disorders Drug Development Pipeline Review, 2018
- Pages: 143
- Published: October 2018
- Report Code: GBIHC048IDB
This report provides an overview of the pipeline landscape for hereditary hematological disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for thalassemia, hemophilia B and sickle cell anemia, and features dormant and discontinued products.
Thalassemia refers to a group of inherited blood disorders that affect the body’s ability to produce hemoglobin and red blood cells. Symptoms include paleness, frequent infections and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant. There are 40 products in development for this indication.
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, nosebleeds and prolonged bleeding from injuries and surgery. Treatment includes replacing the defective clotting factor. There are 42 products in development for this indication.
Sickle cell anemia is a genetic blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. There are 68 products in development for this indication.
Molecular targets acted on by products in development for hereditary hematological disorders include coagulation factors, histone deacetylases and protein kinases. Companies operating in this pipeline space include Sangamo Therapeutics, Gamida Cell and Bluebird Bio.
Scope
– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Companies mentioned
Acceleron Pharma Inc
Agios Pharmaceuticals Inc
Amarna Therapeutics BV
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
ArQule Inc
Bayer AG
Bio Products Laboratory Ltd
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Calimmune Inc
Catalyst Biosciences Inc
Cell Source Inc
China Biologic Products Inc
Epizyme Inc
Expression Therapeutics LLC
Fulcrum Therapeutics Inc
GC Pharma
Global Blood Therapeutics Inc
Homology Medicines, Inc.
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Kiadis Pharma NV
LFB SA
Logicbio Therapeutics Inc
MaxCyte Inc
MimeTech Srl
Morphogenesis Inc
NKT Therapeutics Inc
Novartis AG
Novo Nordisk AS
OPKO Biologics Ltd
Orphagen Pharmaceuticals Inc
Oryzon Genomics SA
Pharming Group NV
Poseida Therapeutics Inc
Prolong Pharmaceuticals LLC
Promethera Biosciences SA
RegenxBio Inc
ReveraGen BioPharma Inc
Sancilio & Company Inc
Sanofi
Shire Plc
Silence Therapeutics Plc
Spark Therapeutics Inc
Syros Pharmaceuticals Inc
UniQure NV
Vifor Pharma AG
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.